Drug Trial Radar · NCT03787602
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Mar 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
115
Planned (sponsor's estimate)
Start
Mar 19, 2019
Primary completion
Nov 2024
Study completion Aug 2025
Sponsor
- Lead sponsor
- Kartos Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
Conditions
- Merkel Cell Carcinoma
Interventions
KRT-232Drug
KRT-232 is an experimental MDM2 anticancer drug taken by mouth.
AvelumabDrug
Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1 Part 1: To determine the KRT-232 RP2D.Time frame: 10 Weeks
- Cohort 1 Part 2: To determine the objective response rate (ORR) in subjects with p53WT MCC who have failed anti-PD-1 or anti-PDL-1 immunotherapyTime frame: 10 Weeks
- Cohort 2 Part 1: To determine the KRT-232 RP2D in combination with avelumabTime frame: 28 Days
- Cohort 2 Part 2: To determine the objective response rate (ORR) in treatment-naïve subjects with p53WT MCCTime frame: 10 Weeks
- Cohort 3: To determine the confirmed overall response rate (ORR) based on IRC assessments in subjects with p53WT MCC are chemotherapy naive and have failed anti-PD-1/PD-L.Time frame: 10 Weeks
- Cohort 4: To determine the confirmed overall response rate (ORR) based on IRC assessments in subjects with p53WT MCC who have failed anti-PD-1 or anti-PDL-1 immunotherapy and have had least 1 line of prior chemotherapy.Time frame: 10 Weeks
Locations
51 sites in 10 countries. Site status is shown where the registry gives one.
University of Colorado Anschutz Medical Campus
Aurora, Colorado · Recruiting
Miami Cancer Institute
Miami, Florida · Recruiting
Moffitt
Tampa, Florida · Recruiting
Northwestern Memorial Hospital
Chicago, Illinois · Recruiting
Norton Healthcare
Louisville, Kentucky · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York · Recruiting
Mount Sinai Hospital
New York, New York · Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Active not recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
University of Texas MD Anderson
Houston, Texas · Recruiting
Inova Health Care Services
Fairfax, Virginia · Recruiting
Princess Alexandra Hospital Oncology
Woolloongabba, Australia · Recruiting
Centro Catarinense de Pesquisa (CECAP) - Hospital Santa Catarina de Blumenau
Blumenau, Brazil · Recruiting
Instituto Nacional do Cancer
Brasília, Brazil · Recruiting
Centro Intergado de Oncologia
Curitiba, Brazil · Recruiting
Centro de Pesquisa Clinica em Oncologia
Ijuí, Brazil · Recruiting
Clinica De Neoplasias Litoral
Itajaí, Brazil · Recruiting
Hospital Paulistano
São Paulo, Brazil · Recruiting
Princess Margaret Cancer Centre
Toronto, Canada · Recruiting
CHU de Bordeaux- Hopital Saint-Andre
Bordeaux, France · Recruiting
AP-HP Universite Paris Saclay
Gif-sur-Yvette, France · Recruiting
CHU de Lille
Lille, France · Recruiting
CHU Lyon-Sud
Lyon, France · Recruiting
Hôpital de la Timone. Aix-Marseille Université
Marseille, France · Recruiting
CHU Montpellier
Montpellier, France · Recruiting
CHU de Nantes
Nantes, France · Recruiting
Hôpital Saint Louis - APHP
Paris, France · Recruiting
CHU de Tours
Tours, France · Recruiting
Vivantes Network for Health Gmb, Neukölln Clinic
Berlin, Germany · Recruiting
Uniklinik Koln
Cologne, Germany · Recruiting
Universitätsklinikum Erlangen
Erlangen, Germany · Recruiting
Universitätsklinikum Essen (AöR)
Essen, Germany · Recruiting
Nationales Centrum für Tumorerkrankungen NCT
Heidelberg, Germany · Recruiting
Universitätsklinik Rostock
Rostock, Germany · Recruiting
Universitats-Hautklinik Tubingen
Tübingen, Germany · Recruiting
Institute for Cancer Research and Treatment
Candiolo, Italy · Recruiting
Istituto Nazionale Tumori IRCCS Fondazione Pascale
Naples, Italy · Recruiting
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.